Videos

Getting a flu shot while pregnant significantly reduces the risk of severe illness for the mother and cuts the infant’s flu risk by 44% during the first 6 months of life.

Discover the serious health risks of smoking while pregnant, how vaping compares, and the most effective ways clinicians can help women quit.

A panelist emphasizes that the OASIS 4 findings, with those of prior OASIS studies, strongly support the use of this drug class for managing vasomotor symptoms (VMS) in patients with breast cancer receiving endocrine therapy and highlights the need for future research in underserved populations such as men with breast cancer and those with metastatic disease.

A panelist explains that although liver function was closely monitored due to potential concerns about the investigational therapy and concurrent endocrine treatments, no serious hepatotoxicity was observed during the trial. However, continued monitoring in longer-term and real-world settings remains important to confirm the treatment’s liver safety profile.

A panelist notes that although the treatment was generally well tolerated—with fatigue, somnolence, and diarrhea being the most common adverse effects—long-term data on breast cancer outcomes such as recurrence and survival are still lacking, underscoring the need for extended follow-up and real-world evidence to fully assess long-term safety and efficacy.

A panelist emphasizes that effectively managing endocrine therapy adverse effects—particularly vasomotor symptoms—can significantly improve treatment adherence, which is critical for reducing recurrence risk and improving survival in patients with breast cancer.

A panelist shares that secondary results from the trial showed early and sustained improvements in sleep and quality of life, underscoring the therapy’s potential to enhance endocrine treatment adherence by alleviating vasomotor symptoms (VMS) that often lead to poor adherence in patients with breast cancer.

The American Medical Association urges plant-based diets, exercise, and reduced alcohol to lower breast cancer risk and address racial disparities.

A new study reveals how provider bias and stigma in reproductive health settings limit care for young, unmarried, and childless women—and how targeted interventions can help reduce these barriers.

A panelist highlights that at ASCO 2025, a landmark phase 3 trial showed a new treatment significantly reduced moderate-to-severe hot flashes in patients with breast cancer receiving endocrine therapy, with rapid and sustained symptom relief and high patient continuation rates over 2 years.

A panelist explains that although hormone replacement therapy is contraindicated in patients with breast cancer due to recurrence risks, new nonhormonal treatments targeting neurokinin receptors in the brain offer promising relief for vasomotor symptoms without interfering with endocrine therapy.

Health care providers are using short-form videos on TikTok to educate young women about Pap tests, breaking down barriers with engaging, accessible content.

New research shows up to 17% of reproductive-aged women visit crisis pregnancy centers, raising alarms over misinformation and lack of regulation.

A panelist notes that although chemotherapy’s adverse effects are intense but short-lived, endocrine therapy for hormone receptor–positive breast cancer involves persistent symptoms over several years, making symptom management essential for patient adherence and quality of life.

A panelist discusses how endocrine therapy remains the cornerstone of treatment for hormone receptor–positive, HER2-negative breast cancer, emphasizing its role in reducing relapse risk and mortality while highlighting the importance of tolerability and individualized care across the subtype’s heterogeneous presentations.

Learn how to identify early symptoms of preeclampsia and improve outcomes with timely screening, diagnosis, and prevention strategies from Eran Bornstein, MD.

Comprehensive first trimester screening can identify over 90% of early preeclampsia cases, allowing timely intervention with low-dose aspirin to significantly reduce risks for both mother and baby.

Learn how postpartum psychosis impacts maternal health, the role of family history, and key steps to identify and prevent this serious but treatable condition.

A universal aspirin initiative at a Bronx hospital increased prescribing rates from 30% to 99% and is now being evaluated for its impact on preeclampsia.

Considerations for reducing blood loss, morbidity, and surgical complexity in patients with large fibroids.

Integrating oral health checks into standard clinical assessments can improve overall patient outcomes and reduce the risk of systemic diseases linked to gum and dental issues.

New research reveals a strong connection between poor oral health, oral microbiota, and heightened pain sensitivity in women with central sensitisation disorders.

Women with dense breast tissue face higher cancer risks and diagnostic challenges, but new research reveals contrast imaging may significantly improve early detection.

Watch some highlights from our discussions with experts presenting at the 2025 ACOG meeting.

A structured surgical approach, imaging tools, and careful platform choice support optimal endometriosis management, according to Trina Mansour, MD, at the 2025 ACOG ACSM.

Tia Welsh, MD, MPH, FACOG, shares new evidence showing that single-use negative pressure wound therapy at -80 mmHg lowers cesarean-section infection rates and healthcare costs more effectively than traditional -125 mmHg therapy.

Amy Valent, DO, MCR, discusses how continuous glucose monitors and smart insulin delivery tools are reshaping individualized care for pregnant patients with diabetes.

Lisa Bayer, MD, MPH, details her presentation at the 2025 ACOG ACSM pain management during IUD placement.

Megan Wasson, DO, discusses surgical precision, imaging, and mentorship to improve endometriosis care at the 2025 ACOG Annual Meeting.

Megan Cohen, MD, MPH, outlines major changes to the CDC’s 2024 contraceptive recommendations, including updated safety classifications, inclusive language, and new guidance for transgender and medically complex patients.